Nov. 26, 2013
Mast Therapeutics, Inc
. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer,
Brian M. Culley
, will present at the 25
Annual Piper Jaffray Healthcare Conference, on
Tuesday, December 3
, 2013 at
4:30 p.m. Eastern time
in the Rutherford Room at The New York Palace Hotel in
Interested parties can access a live audio webcast and slide presentation on the Mast Therapeutics web site at
. An archived presentation will be available on the web site for 30 days.
About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in
, California. The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs. MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow).
The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease, a genetic blood disorder in which sickled cells cause blood flow problems, which can lead to severe pain, irreversible organ damage, and early death. The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in early 2014. More information can be found on the Company's web site at
Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.